Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
QIMC Announces Closing of $17.3 Million Bought Deal Offering, Including Full Exercise of Underwriter's Over-Allotment Option
New Found Gold Closes Bought Deal Financing Including Full Exercise of Underwriters' Over-Allotment Option for Gross Proceeds of $115M
Couloir Capital Is Pleased to Announce That It Has Initiated Research Coverage on Pinnacle Silver and Gold
